46.46.Z - Wholesale of pharmaceutical goods
63.99.Z - Other information service activities not elsewhere classified
70.21.Z - Public relations and communication activities
72.11.Z - Research and experimental development on biotechnology
72.19.Z - Other research and experimental development on natural sciences and engineering
73.11.Z - Advertising agencies activities
73.20.Z - Market research and public opinion polling
74.30.Z - Translation and interpretation activities
82.30.Z - Organisation of conventions and trade shows
85.59.B - Other out-of-school forms of education, not elsewhere classified
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | 16,9 | 21,1 | 37 | 74,9 |
EBITDA | 21,7 | 26,6 | 44,9 | 68,9 |
Short time liabilities | 219,8 | 135,6 | 148,5 | 9,5 |
Equity capital | 233,5 | 247 | 276,1 | 11,8 |
Operating profit (EBIT) | 17,4 | 22,8 | 42,6 | 87 |
Assets | 474,5 | 402,2 | 448,5 | 11,5 |
Net profit (loss) | 12,6 | 15,5 | 29,1 | 87,4 |
Cash | 10,6 | 1,5 | 0,2 | -84,8 |
Liabilities and provisions for liabilities | 241 | 155,2 | 172,4 | 11,1 |
Net income from sale | 426,9 | 557,1 | 740 | 32,8 |
Working assets | 458,7 | 386,5 | 433,9 | 12,3 |
Depreciation | 4,3 | 3,8 | 2,3 | -39,3 |
% | % | % | p.p. | |
Profitability of capital | 5,4 | 6,3 | 10,5 | 4,2 |
Equity capital to total assets | 49,2 | 61,4 | 61,6 | 0,2 |
Gross profit margin | 4 | 3,8 | 5 | 1,2 |
EBITDA Margin | 5,1 | 4,8 | 6,1 | 1,3 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 188 | 89 | 73 | -16 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane